Press releases
- Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy
- Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress
- Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation
- Calliditas Q1 report, January - March 2024
- In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action
- Invitation to the presentation of Calliditas´s interim report January - March 2024
- Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm
- Notice of annual general meeting of Calliditas Therapeutics AB (publ)
- Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China
- Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
More ▼
Key statistics
On Friday, Calliditas Therapeutics AB (0A5R:LSE) closed at 208.13, -0.03% below its 52-week high of 208.20, set on May 31, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 208.13 |
Average volume | 221.22k |
---|---|
Shares outstanding | 59.58m |
Free float | 49.57m |
P/E (TTM) | -- |
Market cap | 12.40bn SEK |
EPS (TTM) | -9.78 SEK |
Data delayed at least 20 minutes, as of May 31 2024 17:34 BST.
More ▼